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INTRODUCTION
Glucagonoma syndrome is a rare disease that is usually 
associated with an underlying neuroendocrine tumor. Necro-
lytic Migratory Erythema (NME) has been associated with 
intestinal malabsorption disorders, hepatic cirrhosis, chronic 
pancreatitis, inflammatory bowel disease, and non-pancreatic 
malignancies, but may not always be associated with gluca-
gonoma. In 1979, Mallinson and co-workers coined the term 
glucagonoma syndrome to describe alpha-cell pancreatic 
tumors associated with a characteristic erosive skin eruption, 
termed Necrolytic Migratory Erythema by Wilkinson. NME 
is characterized by an irregular annular eruption with serpigi-
nous advancing borders, erosion, and crusting, resulting in a 
scalded appearance. The eruption has a cyclical nature with 
concurrent lesions at different levels of healing. 
Here, we report two patients with NME associated with 
hyperglucagonemia and neuroendocrine tumor.
CASE 1
This case involved a 66-year-old Brazilian male with an 
eight year history of recurrent cutaneous lesions. 
Abdominal surgery was performed due to colon cancer 
eight years before the dermatologic complaint. He also men-
tioned a significant alcohol history. Physical examination 
revealed erythematous, erosive scaling and crusted patches 
on the genital and groin area (Figure 1). He also presented 
with similar lesions in the perioral and periocular areas as-
sociated with angular cheilitis and a depapilated, bright red 
tongue (Figure 2). The patient denied intestinal symptoms 
and weight loss.
Laboratory testing showed normocytic normochromic 
anemia and slightly elevated levels of amylase and lipase. 
The patient had normal levels of serum zinc, folic acid, 
vitamin B12, albumin, globulins, alanine and aspartate 
tranferase. Hepatitis B and C and HIV serologies were 
negative. An elevated level of blood glucose (125mg/ml) was 
observed. The patient’s plasma level of glucagon was greater 
than 1,280 pg/ml (normal range: <60 pg/ml). 
An abdominal computed tomography (CT) scan revealed 
a hypervascularized tumor measuring 6.1 x 3.8 cm in the 
body and the caudal portion of the pancreas, and an absence 
of liver metastasis. The patient was then subjected to a pan-
createctomy, and the cutaneous lesions vanished one week 
after surgery.
Figure 1 - Erosive scaling and crusted patches on the genital and groin 
area
Figure 2 - Angular cheilitis and a depapilated bright red tongue
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CASE 2
A 62-year-old Brazilian man was referred to our Der-
matology Department complaining of two years of eroded 
skin. The eruption had a cyclical pattern, with periods of 
resolution.
During a weight loss investigation six months prior, a 
CT scan was performed and a pancreatic tumor with hepatic 
metastasis was confirmed. Surgical removal of the tumor was 
not possible. The patient had an episode of deep vein throm-
bosis associated with pulmonary embolism two months prior 
to being referred to our department earlier, and was taking 
marevan. 
Physical examination revealed erythematous scaling 
and crusted plaques, with exulceration on the edges of the 
lesions, involving the groin and genital areas (Figure 3) 
and the periorbital area (Figure 4). He also presented with 
tense bullous lesions with purulent content and pellagroid 
eczematous plaques on the anterior surface of the legs and 
feet, associated with purpura and edema (Figure 5). Angular 
cheilitis and a depapilated red tongue were also present. 
In addition to the skin changes, the patient complained of 
weight loss and watery diarrhea.
Laboratory testing revealed normocytic normochromic 
anemia, hypoalbuminemia and elevated levels of amylase, 
lipase, alkaline phosphatase, gamma glutamyl transferase, 
alanine and aspartate transferase. Plasma levels of glucose 
and zinc were normal. The patient’s fasting plasma glucagon 
level was 1,280 pg/ml (normal range: <60 pg/ml), and amino 
acid levels were decreased.
An ultrasound-guided needle biopsy of a hepatic lesion 
was performed, and histopathological examination and im-
munohistochemistry revealed a neuroendocrine tumor.
Histopathological examination of a purpuric skin lesion 
showed extravasated erythrocytes on the superficial dermis 
and hyaline thrombus on the vascular lumen of on the deep 
dermis. These findings were attributed to the medication 
taken by the patient. 
Palliative treatment with interferon alpha and octreotide 
LAR was proposed, but the patient presented an erythema-
tous rash that was attributed to interferon alpha. Therefore, 
the offending drug was suspended. Octreotide LAR, 20 mg/
month, was continued with complete resolution of the skin 
lesions. The patient was discharged and prescribed ambula-
tory chemotherapy.
DISCUSSION
Glucagonoma arises from alpha cells of pancreatic islets 
of Langerhans and may appear as either a benign, localized 
alpha cell adenoma, or a slow growing metastasizing malig-
nant tumor. Glucagonoma is associated with striking system-
ic clinical manifestations, referred to as the “Glucagonoma Figure 3 - Erythematous scaling and crusted plaques, with exulceration on 
the edges of the lesions, involving the groin and genital areas
Figure 4 - Erythematous scaling and crusted plaques, with exulceration on 
the edges of the lesions, involving the periorbital area
Figure 5 - Tense bullous lesions with purulent content and pellagroid 
eczematous plaques on the anterior surface of the legs and feet, associated 
with purpura and edema
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Syndrome.” Systemic manifestations of the syndrome are 
numerous, and include diabetes mellitus, anemia, venous 
thrombosis, skin rash (NME), weight loss, glossitis, cheilitis, 
diarrhea, steatorrhea, and psychiatric disorders.
The cause of skin changes in NME is unclear. Glucagon 
per se has not been found to be the direct cause because 
there are patients who present with NME without neuroen-
docrine tumors or hyperglucagonemia. However, normaliza-
tion of glucagon concentration by surgery or somatostatin 
analogs almost invariably results in a rapid resolution of 
the skin lesions. Furthermore, there is a recent report of a 
case of iatrogenic NME after intravenous administration of 
glucagon for the treatment of persistent hypoglycemia13 due 
to an insulinoma. This case supports the hypothesis of glu-
cagon leading to the skin lesions. Zinc, essential fatty acid, 
and amino acid deficiencies are all considered to be possible 
causes of NME. However, not all patients with skin lesions 
present with these metabolic changes, and not all patients 
with these metabolic changes present with resolution of the 
skin lesions after zinc, essential fatty acid, or amino acid 
supplementation.14
NME is a rare dermatosis that is usually associated with 
an underlying pancreatic islet cell tumor. The skin eruption 
may be the first manifestation of the disease, and its recogni-
tion may lead to a diagnosis, as in case 1. The eruption has 
a cyclic nature, with periods of skin lesion resolution, as ob-
served in both of our cases. The lesions consist of erythema-
tous scaling and crusting patches most frequently observed 
in areas of trauma, such as the groin, intergluteal, and genital 
areas. Bullous lesions may occur. Cheilitis and glossitis are 
very common mucosal manifestations. It is commonly ob-
served that these patients present with a history of antibiotic 
or antifungal treatments without improvements of their skin 
conditions before the correct diagnosis is made. 
The histopathologic features of NME are nonspecific 
and may be seen in pellagra, necrolytic acral erythema, or 
zinc deficiency. Vacuolated, pale, swollen epidermal cells 
and necrosis of the superficial epidermis are characteristic 
(Figure 6). Biopsy specimens from the edges of active le-
sions are most likely to show the characteristic upper epi-
dermal necrosis; however, many biopsy specimens do not 
have features that are typical, or even suggestive, of NME. 
Therefore, multiple biopsies are recommended when this 
diagnosis is suspected. 
Diagnostic criteria of glucagonoma syndrome have been 
proposed by Stacpole and include demonstration of a tumor 
producing increased levels of glucagon, as revealed by spe-
cial staining and increased circulatory levels of glucagon. In 
addition, the patient must meet at least one of the following 
criteria: (1) skin eruption, (2) diabetes mellitus, and (3) hy-
poaminoacidemia.
Glucagonomas show significant evidence of hypervas-
cularity, so selective celiac and superior mesenteric arte-
riographies are the most reliable ways to detect the primary 
neoplasm if the abdominal CT scan does not disclose the tu-
mor. Histopatologic confirmation of the glucagonoma occurs 
via immunohistochemistry, electronic microscope analysis, 
and in situ hybridization of glucagon messenger RNA. The 
absence of immunoreactivity for glucagon or glucagon mes-
senger RNA transcripts in a metastatic focus may be due to 
tumor heterogeneity since glucagon may not be expressed in 
all metastatic foci. This could explain the negative immuno-
histochemistry for glucagon in case 2. Usually, the antigens 
used to assess neuroendocrine differentiation of tumors are 
synaptophysin and cromogranin. Hormones such as insulin, 
glucagon, vasointestinal polypeptide, somatostatin, and 
pancreatic polypeptide are used to determine the predomi-
nant hormone produced by tumors. In some cases, tumors 
produce more than one hormone.
The prognosis of the disease varies greatly according to 
the stage in which the tumor is diagnosed. By the time of di-
agnosis, 50-100% of patients already present with metastatic 
disease, and a cure is often impossible, as in case 2. The 
tumor is resistant to chemotherapy, and metastatic disease is 
often not amenable to surgical resection9. However, since this 
islet cell tumor is slow-growing, prolonged survival (more 
than 20 years) is possible, and in metastatic disease, most 
causes of death appear to be unrelated to the tumor.17
Successful palliative treatment is possible with long-
acting somatostatin analogs,22,26 and/or interferon alpha. 
Supplementation with zinc, amino acids, and essential fatty 
acids appears to be beneficial in some cases.12,14
The patient in case 1 was a diagnostic challenge. Only 
skin lesions and mucosal changes were present at the time 
of diagnosis. In this case, the dermatologist was responsible 
for the pancreatic tumor diagnosis in the curable stage of 
disease.
Figure 6 - Vacuolated, pale, swollen epidermal cells and necrosis of the 
superficial epidermis
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In case 2, it was not possible to perform a surgical resec-
tion of the tumor, so only an improvement in the skin lesions 
was feasible.
We describe two cases that illustrated good outcomes of 
skin lesions in two different situations: case 1 was a patient 
with an early diagnosis and a curable disease and case 2 was 
a patient with a metastatic tumor. Both patients presented 
with resolution of skin lesions after beginning treatment. 
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